FDA clears Curium’s BEXLUTRY, a Lutathera-equivalent radioligand therapy on September 15, 2026 BEXLUTRY Curium dotatate GEP-NETs Lutathera lutetium Novartis patent litigation radioligand therapy United States Food and Drug Administration +